We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00646737
First Posted: March 28, 2008
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis
  Purpose
The purpose of this study is to evaluate the safety and the tolerability of the substitution of mycophenolate mofetil for enteric-coated mycophenolate sodium in a population of stable renal transplant patients in Brazil, in a treatment regimen of immunosuppressants with tacrolimus and mycophenolate mofetil.

Condition Intervention Phase
Kidney Transplantation Drug: Mycophenolate sodium Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IV Study of Enteric-coated Mycophenolate Sodium in Combination With Tacrolimus in Renal Transplant Patient

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Gastrointestinal symptoms in renal transplant patients treated with the immunosuppression regimen of tacrolimus and mycophenolate at baseline, 8 and 16 weeks [ Time Frame: 8 and 16 weeks ]

Secondary Outcome Measures:
  • Impact of gastrointestinal symptoms on quality of life. Tolerability of mycophenolate sodium in combination with tacrolimus assessed by OSRS. Safety of mycophenolate sodium in combination with tacrolimus assessed by incidence of adverse events [ Time Frame: 8 and 16 weeks ]

Enrollment: 18
Study Start Date: May 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Mycophenolate sodium
Drug: Mycophenolate sodium
Mycophenolate sodium

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Age between 18 and 65 years;
  • First or second renal transplant within at least 12 weeks;
  • Clinical stability, in the opinion of the investigator, during at least 8 weeks before inclusion in the study;
  • Women of reproductive age must use contraceptive methods and present negative results in pregnancy test Serum creatinine < 2.5 mg/dE; Patients in use of a immunosuppression regimen based on tacrolimus and mycophenolate mofetil (generic or not, in any dose), who present gastrointestinal symptoms Capacity to complete the study requirements;

Exclusion criteria History of acute rejection,

  • Proven or not by biopsy, in the last 2 months before the study;
  • Recipients of multiple organs;
  • Participation in any clinical investigation in the last 6 months before the present study;
  • Thrombocytopenia (platelets <75,00O/mm3), leucopenia (total leukocytes <4,000/mm3)and/or anemia (hemoglobin <9.0 gldL) before inclusion in the study;
  • Clinically important disease, in the opinion of the investigator, including systemic infection, within 2 weeks before inclusion in the study;
  • Presence of any neoplasia, current or past, except resected basal cell carcinoma;
  • Any surgical or medical condition that could significantly alter the absorption, distribution, metabolism or excretion of medicines or that could put the patient in danger as a result of participation in the study;
  • History of drug or alcohol abuse within previous 12 months of inclusion in the study, Current or prior use in the last 2 months of bile acid-adsorbing resins(cholestyramine and colestipol).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00646737


Locations
Brazil
Novartis Investigative Site
Sao Paulo, Brazil
Sponsors and Collaborators
Novartis
Investigators
Study Director: Novartis Novartis
  More Information

Additional Information:
Publications:
Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT00646737     History of Changes
Other Study ID Numbers: CERL080ABR02
First Submitted: March 18, 2008
First Posted: March 28, 2008
Last Update Posted: February 23, 2017
Last Verified: February 2017

Keywords provided by Novartis:
Kidney transplantation
conversion
mycophenolate mofetil
mycophenolate sodium,
tacrolimus

Additional relevant MeSH terms:
Tacrolimus
Mycophenolate mofetil
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents